| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 23 | 2023 | 425 | 3.340 |
Why?
|
| Prostatic Neoplasms | 39 | 2023 | 5767 | 2.660 |
Why?
|
| Androgen Antagonists | 8 | 2023 | 411 | 1.760 |
Why?
|
| Anilides | 10 | 2022 | 268 | 1.330 |
Why?
|
| Bone Neoplasms | 15 | 2022 | 2576 | 1.240 |
Why?
|
| Taxoids | 5 | 2020 | 967 | 1.240 |
Why?
|
| Carcinoma, Renal Cell | 16 | 2022 | 2326 | 1.090 |
Why?
|
| Kidney Neoplasms | 16 | 2022 | 3022 | 0.960 |
Why?
|
| Pyridines | 11 | 2022 | 1244 | 0.960 |
Why?
|
| Antineoplastic Agents | 25 | 2023 | 14289 | 0.930 |
Why?
|
| Hypoxia-Inducible Factor 1 | 3 | 2008 | 55 | 0.910 |
Why?
|
| Cell Hypoxia | 3 | 2008 | 328 | 0.840 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2021 | 15862 | 0.790 |
Why?
|
| Pyrroles | 6 | 2015 | 576 | 0.760 |
Why?
|
| Indoles | 6 | 2015 | 1009 | 0.680 |
Why?
|
| DNA Methylation | 5 | 2011 | 2669 | 0.660 |
Why?
|
| Signal Transduction | 18 | 2023 | 11965 | 0.650 |
Why?
|
| Gene Expression Regulation, Neoplastic | 16 | 2019 | 8873 | 0.640 |
Why?
|
| Biomarkers, Tumor | 15 | 2021 | 10331 | 0.640 |
Why?
|
| Fibroblast Growth Factors | 3 | 2021 | 257 | 0.620 |
Why?
|
| Prostate-Specific Antigen | 9 | 2021 | 993 | 0.610 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 8 | 2023 | 479 | 0.600 |
Why?
|
| Bridged-Ring Compounds | 1 | 2017 | 183 | 0.600 |
Why?
|
| DNA Damage | 8 | 2017 | 1954 | 0.570 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2015 | 1823 | 0.570 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2017 | 112 | 0.560 |
Why?
|
| Receptors, Androgen | 9 | 2020 | 878 | 0.560 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2020 | 840 | 0.530 |
Why?
|
| Male | 81 | 2023 | 123000 | 0.530 |
Why?
|
| Cell Cycle | 5 | 2021 | 2084 | 0.520 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 2 | 2021 | 32 | 0.510 |
Why?
|
| Phenylthiohydantoin | 5 | 2023 | 89 | 0.500 |
Why?
|
| Phthalazines | 5 | 2021 | 253 | 0.490 |
Why?
|
| Abiraterone Acetate | 5 | 2021 | 70 | 0.490 |
Why?
|
| Tumor Microenvironment | 9 | 2023 | 2864 | 0.490 |
Why?
|
| Castration | 2 | 2014 | 122 | 0.490 |
Why?
|
| src-Family Kinases | 2 | 2014 | 478 | 0.480 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2015 | 3552 | 0.460 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2008 | 622 | 0.460 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2023 | 5178 | 0.440 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2007 | 589 | 0.440 |
Why?
|
| Humans | 98 | 2023 | 261506 | 0.420 |
Why?
|
| Apoptosis | 13 | 2021 | 7591 | 0.420 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2010 | 528 | 0.410 |
Why?
|
| Neoplasm Metastasis | 14 | 2021 | 5112 | 0.400 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 79 | 0.400 |
Why?
|
| Extracellular Vesicles | 2 | 2023 | 135 | 0.370 |
Why?
|
| Poly(ADP-ribose) Polymerases | 4 | 2021 | 324 | 0.370 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2008 | 155 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 9 | 2017 | 4757 | 0.360 |
Why?
|
| Quality of Life | 2 | 2023 | 4532 | 0.360 |
Why?
|
| Immunotherapy | 4 | 2021 | 3341 | 0.350 |
Why?
|
| Piperazines | 6 | 2021 | 2101 | 0.350 |
Why?
|
| Genetic Heterogeneity | 1 | 2011 | 318 | 0.350 |
Why?
|
| Pyrimidines | 7 | 2021 | 3518 | 0.340 |
Why?
|
| Aged | 39 | 2023 | 70117 | 0.340 |
Why?
|
| Aged, 80 and over | 29 | 2021 | 29902 | 0.340 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2008 | 376 | 0.340 |
Why?
|
| Genes, p53 | 3 | 2010 | 1090 | 0.330 |
Why?
|
| Sulfonamides | 5 | 2021 | 1823 | 0.330 |
Why?
|
| Prostate | 4 | 2023 | 1088 | 0.330 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2021 | 607 | 0.320 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2008 | 73 | 0.310 |
Why?
|
| eIF-2 Kinase | 1 | 2009 | 164 | 0.310 |
Why?
|
| Sirolimus | 3 | 2019 | 814 | 0.300 |
Why?
|
| Urogenital Neoplasms | 2 | 2021 | 108 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2010 | 507 | 0.300 |
Why?
|
| Cytidine | 1 | 2006 | 24 | 0.290 |
Why?
|
| Cell Line, Tumor | 18 | 2023 | 14551 | 0.290 |
Why?
|
| Indazoles | 5 | 2021 | 297 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2015 | 419 | 0.280 |
Why?
|
| Middle Aged | 39 | 2021 | 86204 | 0.270 |
Why?
|
| Cytoprotection | 1 | 2005 | 66 | 0.270 |
Why?
|
| Neoplasm Proteins | 3 | 2009 | 3230 | 0.270 |
Why?
|
| Cancer Vaccines | 1 | 2011 | 697 | 0.270 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2022 | 854 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 3 | 2017 | 2330 | 0.260 |
Why?
|
| Hypoxia | 1 | 2008 | 443 | 0.260 |
Why?
|
| Cell Cycle Proteins | 4 | 2017 | 2045 | 0.260 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2023 | 192 | 0.260 |
Why?
|
| CpG Islands | 2 | 2008 | 633 | 0.260 |
Why?
|
| Tissue Extracts | 2 | 2017 | 48 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2008 | 810 | 0.250 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 1290 | 0.250 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2022 | 1248 | 0.250 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2023 | 716 | 0.250 |
Why?
|
| Nitriles | 5 | 2019 | 906 | 0.240 |
Why?
|
| Ipilimumab | 3 | 2021 | 710 | 0.240 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2016 | 142 | 0.230 |
Why?
|
| Adenocarcinoma | 3 | 2013 | 7789 | 0.230 |
Why?
|
| Kallikreins | 2 | 2021 | 84 | 0.230 |
Why?
|
| Urinary Tract | 1 | 2023 | 82 | 0.220 |
Why?
|
| Treatment Outcome | 23 | 2021 | 32848 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2021 | 3821 | 0.220 |
Why?
|
| RNA-Binding Proteins | 1 | 2008 | 984 | 0.210 |
Why?
|
| Carboplatin | 3 | 2020 | 823 | 0.210 |
Why?
|
| DNA, Neoplasm | 1 | 2007 | 1910 | 0.210 |
Why?
|
| Peptide Hydrolases | 1 | 2003 | 256 | 0.200 |
Why?
|
| Animals | 22 | 2023 | 59536 | 0.200 |
Why?
|
| Neuroectodermal Tumors | 1 | 2021 | 35 | 0.200 |
Why?
|
| Cell Differentiation | 3 | 2021 | 4078 | 0.200 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2019 | 82 | 0.200 |
Why?
|
| Testosterone | 2 | 2023 | 619 | 0.190 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2021 | 1756 | 0.190 |
Why?
|
| Epigenesis, Genetic | 1 | 2008 | 1399 | 0.190 |
Why?
|
| Cyclobutanes | 1 | 2021 | 36 | 0.190 |
Why?
|
| CDC2 Protein Kinase | 1 | 2021 | 176 | 0.190 |
Why?
|
| Carboxylic Acids | 1 | 2021 | 57 | 0.190 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2021 | 182 | 0.190 |
Why?
|
| Androstenes | 3 | 2020 | 41 | 0.190 |
Why?
|
| CTLA-4 Antigen | 2 | 2021 | 657 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 129 | 0.190 |
Why?
|
| Mice | 18 | 2023 | 34495 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 198 | 0.180 |
Why?
|
| Radium | 1 | 2021 | 93 | 0.180 |
Why?
|
| Genome, Human | 1 | 2008 | 1869 | 0.180 |
Why?
|
| Prostatectomy | 2 | 2021 | 962 | 0.180 |
Why?
|
| Drug Combinations | 2 | 2014 | 621 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 4 | 2023 | 4367 | 0.180 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 2315 | 0.170 |
Why?
|
| Hypokalemia | 1 | 2019 | 55 | 0.170 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2014 | 661 | 0.170 |
Why?
|
| Neoplasm Grading | 5 | 2016 | 1742 | 0.170 |
Why?
|
| Dehydration | 1 | 2019 | 87 | 0.170 |
Why?
|
| Prognosis | 8 | 2020 | 21713 | 0.170 |
Why?
|
| Incidental Findings | 1 | 2021 | 272 | 0.170 |
Why?
|
| Survival Rate | 8 | 2021 | 12221 | 0.170 |
Why?
|
| Platinum | 2 | 2017 | 138 | 0.170 |
Why?
|
| Benzimidazoles | 3 | 2021 | 428 | 0.170 |
Why?
|
| Urothelium | 1 | 2020 | 254 | 0.170 |
Why?
|
| Imidazoles | 3 | 2014 | 999 | 0.170 |
Why?
|
| Urologic Neoplasms | 1 | 2021 | 188 | 0.170 |
Why?
|
| Anorexia | 1 | 2019 | 143 | 0.160 |
Why?
|
| RNA, Messenger | 2 | 2008 | 6150 | 0.160 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 338 | 0.160 |
Why?
|
| Radiation Oncology | 1 | 2023 | 529 | 0.160 |
Why?
|
| Clonal Evolution | 1 | 2020 | 253 | 0.160 |
Why?
|
| Seminal Vesicles | 2 | 2020 | 152 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2020 | 224 | 0.160 |
Why?
|
| Gene Expression Regulation | 2 | 2023 | 4053 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 2508 | 0.150 |
Why?
|
| Neutropenia | 2 | 2019 | 968 | 0.150 |
Why?
|
| Bone and Bones | 3 | 2015 | 619 | 0.150 |
Why?
|
| Benzamides | 4 | 2019 | 1832 | 0.150 |
Why?
|
| Etoposide | 3 | 2009 | 870 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2021 | 1048 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2023 | 2341 | 0.150 |
Why?
|
| Orchiectomy | 3 | 2013 | 214 | 0.150 |
Why?
|
| Prednisone | 4 | 2021 | 984 | 0.150 |
Why?
|
| Combined Modality Therapy | 5 | 2020 | 8865 | 0.150 |
Why?
|
| Thiophenes | 2 | 2017 | 148 | 0.150 |
Why?
|
| Neutrophils | 1 | 2021 | 835 | 0.150 |
Why?
|
| Filgrastim | 1 | 2016 | 191 | 0.150 |
Why?
|
| BRCA1 Protein | 2 | 2017 | 493 | 0.140 |
Why?
|
| Bevacizumab | 4 | 2015 | 938 | 0.140 |
Why?
|
| Nuclear Proteins | 5 | 2017 | 3343 | 0.140 |
Why?
|
| Neoplasms | 4 | 2017 | 15193 | 0.140 |
Why?
|
| Urea | 2 | 2017 | 290 | 0.140 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 3251 | 0.140 |
Why?
|
| Chemokine CXCL1 | 1 | 2016 | 60 | 0.140 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 5159 | 0.140 |
Why?
|
| Thiazoles | 2 | 2011 | 726 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 598 | 0.140 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2017 | 174 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2020 | 1064 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2011 | 15694 | 0.140 |
Why?
|
| Osteopontin | 1 | 2016 | 148 | 0.140 |
Why?
|
| Disease Progression | 7 | 2016 | 6682 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 2 | 2015 | 5061 | 0.130 |
Why?
|
| Cell Proliferation | 6 | 2021 | 7226 | 0.130 |
Why?
|
| Diarrhea | 1 | 2019 | 686 | 0.130 |
Why?
|
| Cisplatin | 4 | 2023 | 2432 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 1301 | 0.130 |
Why?
|
| DNA-Binding Proteins | 4 | 2017 | 4821 | 0.130 |
Why?
|
| DNA Repair | 3 | 2017 | 1872 | 0.130 |
Why?
|
| Dasatinib | 3 | 2020 | 862 | 0.130 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 79 | 0.130 |
Why?
|
| Caveolin 1 | 1 | 2016 | 204 | 0.130 |
Why?
|
| Female | 25 | 2022 | 141928 | 0.130 |
Why?
|
| Adult | 22 | 2021 | 77950 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 833 | 0.130 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 3719 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5319 | 0.130 |
Why?
|
| Drug Approval | 1 | 2016 | 178 | 0.130 |
Why?
|
| Strontium Radioisotopes | 1 | 2014 | 26 | 0.130 |
Why?
|
| Disease-Free Survival | 9 | 2021 | 10001 | 0.120 |
Why?
|
| Bone Remodeling | 2 | 2012 | 104 | 0.120 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2014 | 36 | 0.120 |
Why?
|
| Bone Marrow Cells | 2 | 2016 | 943 | 0.120 |
Why?
|
| Neoplasm Staging | 8 | 2020 | 13658 | 0.120 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 2216 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2015 | 1546 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2008 | 2947 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2014 | 47 | 0.120 |
Why?
|
| Biomarkers | 2 | 2023 | 5047 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 846 | 0.120 |
Why?
|
| Gene Expression | 2 | 2021 | 3570 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 272 | 0.120 |
Why?
|
| Naphthalenes | 1 | 2014 | 83 | 0.120 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2020 | 1249 | 0.120 |
Why?
|
| RANK Ligand | 2 | 2011 | 119 | 0.120 |
Why?
|
| Anemia | 1 | 2019 | 689 | 0.120 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 355 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 3 | 2016 | 1547 | 0.120 |
Why?
|
| Tosyl Compounds | 1 | 2013 | 40 | 0.110 |
Why?
|
| Quinolones | 1 | 2014 | 160 | 0.110 |
Why?
|
| Goserelin | 1 | 2013 | 18 | 0.110 |
Why?
|
| Mice, Nude | 5 | 2021 | 4307 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2021 | 1664 | 0.110 |
Why?
|
| Gene Deletion | 2 | 2009 | 1442 | 0.110 |
Why?
|
| Protein Binding | 2 | 2014 | 3438 | 0.110 |
Why?
|
| Fatigue | 1 | 2019 | 1239 | 0.110 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 615 | 0.110 |
Why?
|
| Neuroendocrine Tumors | 1 | 2019 | 634 | 0.110 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2013 | 153 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 1533 | 0.110 |
Why?
|
| Leuprolide | 1 | 2013 | 65 | 0.110 |
Why?
|
| Survival Analysis | 7 | 2021 | 9180 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2014 | 588 | 0.110 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 11538 | 0.110 |
Why?
|
| Ovarian Neoplasms | 2 | 2008 | 4638 | 0.110 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 321 | 0.110 |
Why?
|
| Lipids | 1 | 2016 | 644 | 0.110 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 3 | 2021 | 430 | 0.110 |
Why?
|
| Busulfan | 2 | 2014 | 764 | 0.100 |
Why?
|
| Androstenols | 1 | 2011 | 10 | 0.100 |
Why?
|
| Clusterin | 1 | 2011 | 28 | 0.100 |
Why?
|
| Mice, SCID | 2 | 2017 | 1869 | 0.100 |
Why?
|
| Endothelin-1 | 1 | 2011 | 60 | 0.100 |
Why?
|
| Depression | 1 | 2021 | 1715 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2013 | 553 | 0.100 |
Why?
|
| Pyrrolidines | 1 | 2011 | 113 | 0.100 |
Why?
|
| Denosumab | 1 | 2011 | 68 | 0.100 |
Why?
|
| Proteins | 1 | 2019 | 1963 | 0.100 |
Why?
|
| Doxorubicin | 3 | 2015 | 3005 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2021 | 3472 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 1077 | 0.090 |
Why?
|
| Transcriptome | 2 | 2017 | 1859 | 0.090 |
Why?
|
| Phosphorylation | 3 | 2017 | 4804 | 0.090 |
Why?
|
| Insulin | 1 | 2016 | 1454 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2013 | 2292 | 0.090 |
Why?
|
| Time Factors | 7 | 2021 | 12926 | 0.090 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2010 | 142 | 0.090 |
Why?
|
| Epigenomics | 1 | 2011 | 266 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 612 | 0.090 |
Why?
|
| Chromosomes, Human, X | 1 | 2010 | 192 | 0.090 |
Why?
|
| Genes, cdc | 1 | 2009 | 81 | 0.090 |
Why?
|
| Caspases, Initiator | 1 | 2009 | 16 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2021 | 5395 | 0.080 |
Why?
|
| Carcinoma | 1 | 2020 | 2578 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2010 | 195 | 0.080 |
Why?
|
| Osteoclasts | 1 | 2009 | 165 | 0.080 |
Why?
|
| Collagen | 2 | 2009 | 752 | 0.080 |
Why?
|
| Retrospective Studies | 11 | 2021 | 37905 | 0.080 |
Why?
|
| Cell Movement | 1 | 2016 | 2466 | 0.080 |
Why?
|
| Research Design | 1 | 2016 | 1544 | 0.080 |
Why?
|
| Cell Death | 1 | 2010 | 671 | 0.080 |
Why?
|
| Laminin | 1 | 2008 | 194 | 0.080 |
Why?
|
| Proteomics | 1 | 2015 | 1380 | 0.080 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2015 | 962 | 0.080 |
Why?
|
| Models, Biological | 2 | 2008 | 3254 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2011 | 1391 | 0.080 |
Why?
|
| Mitosis | 2 | 2017 | 615 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2483 | 0.080 |
Why?
|
| Proteoglycans | 1 | 2008 | 259 | 0.080 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2009 | 301 | 0.080 |
Why?
|
| Pneumonia | 1 | 2013 | 751 | 0.080 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 14889 | 0.080 |
Why?
|
| Endoplasmic Reticulum | 1 | 2009 | 308 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 3578 | 0.070 |
Why?
|
| Osteoblasts | 2 | 2022 | 370 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2008 | 249 | 0.070 |
Why?
|
| Proteasome Inhibitors | 1 | 2007 | 231 | 0.070 |
Why?
|
| Prospective Studies | 5 | 2022 | 12873 | 0.070 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 7548 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2010 | 889 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2359 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2009 | 492 | 0.070 |
Why?
|
| Pain | 1 | 2014 | 1658 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2022 | 4557 | 0.060 |
Why?
|
| Translocation, Genetic | 1 | 2010 | 1245 | 0.060 |
Why?
|
| Single-Cell Analysis | 2 | 2020 | 470 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 3203 | 0.060 |
Why?
|
| Leukemia, Myeloid | 1 | 2009 | 941 | 0.060 |
Why?
|
| Nephrectomy | 1 | 2009 | 779 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2009 | 852 | 0.060 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 1371 | 0.060 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2017 | 278 | 0.060 |
Why?
|
| Biopsy | 3 | 2016 | 3443 | 0.060 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2003 | 85 | 0.060 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 82 | 0.060 |
Why?
|
| Mifepristone | 1 | 2023 | 147 | 0.060 |
Why?
|
| Obesity | 1 | 2016 | 2884 | 0.060 |
Why?
|
| Hydrolysis | 1 | 2003 | 227 | 0.060 |
Why?
|
| Endothelial Cells | 2 | 2022 | 1048 | 0.060 |
Why?
|
| Promoter Regions, Genetic | 2 | 2008 | 3101 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 10035 | 0.060 |
Why?
|
| Phenylurea Compounds | 2 | 2021 | 580 | 0.060 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2003 | 109 | 0.050 |
Why?
|
| Mutation | 4 | 2023 | 15179 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2017 | 1313 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2005 | 1643 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 2104 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 1516 | 0.050 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2022 | 365 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2009 | 3033 | 0.050 |
Why?
|
| Caspases | 1 | 2003 | 661 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 4988 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 3981 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 1879 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 709 | 0.040 |
Why?
|
| Tretinoin | 1 | 2022 | 623 | 0.040 |
Why?
|
| Indolizines | 1 | 2019 | 45 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2019 | 34 | 0.040 |
Why?
|
| Pyridinium Compounds | 1 | 2019 | 63 | 0.040 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2019 | 61 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2021 | 212 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 3154 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2023 | 5270 | 0.040 |
Why?
|
| Cyclic N-Oxides | 1 | 2019 | 106 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2020 | 756 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 7222 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 703 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2021 | 565 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6207 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2019 | 6869 | 0.040 |
Why?
|
| E2F1 Transcription Factor | 1 | 2019 | 206 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2019 | 409 | 0.040 |
Why?
|
| Exosomes | 1 | 2021 | 253 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2021 | 9244 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2023 | 1353 | 0.040 |
Why?
|
| Cell Line | 1 | 2005 | 5114 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 383 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2017 | 96 | 0.040 |
Why?
|
| United States | 3 | 2021 | 15433 | 0.040 |
Why?
|
| Risk | 1 | 2021 | 1972 | 0.040 |
Why?
|
| Coordination Complexes | 1 | 2017 | 17 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2020 | 519 | 0.040 |
Why?
|
| Base Sequence | 1 | 2003 | 4917 | 0.040 |
Why?
|
| Fatty Acid Synthase, Type I | 1 | 2016 | 11 | 0.040 |
Why?
|
| Receptors, Interleukin-8A | 1 | 2016 | 16 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2023 | 1549 | 0.040 |
Why?
|
| Aurora Kinase A | 1 | 2017 | 202 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 1183 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 1375 | 0.040 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2016 | 54 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 3639 | 0.040 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2016 | 56 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2023 | 1824 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 6089 | 0.030 |
Why?
|
| Homologous Recombination | 1 | 2017 | 185 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1000 | 0.030 |
Why?
|
| DNA Adducts | 1 | 2017 | 210 | 0.030 |
Why?
|
| Young Adult | 4 | 2016 | 21445 | 0.030 |
Why?
|
| RNA | 1 | 2021 | 1013 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2016 | 99 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 68 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 208 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 3 | 2015 | 4975 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 733 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 2803 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2015 | 3890 | 0.030 |
Why?
|
| Vinblastine | 1 | 2015 | 453 | 0.030 |
Why?
|
| Capecitabine | 1 | 2015 | 388 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 241 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2002 | 1818 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 760 | 0.030 |
Why?
|
| Adipocytes | 1 | 2016 | 305 | 0.030 |
Why?
|
| Tumor Protein p73 | 1 | 2014 | 105 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2014 | 223 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 2170 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 519 | 0.030 |
Why?
|
| Cell Membrane Permeability | 1 | 2014 | 122 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2015 | 543 | 0.030 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 332 | 0.030 |
Why?
|
| United Kingdom | 1 | 2014 | 257 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2019 | 923 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 395 | 0.030 |
Why?
|
| Actins | 1 | 2016 | 608 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 660 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 1053 | 0.030 |
Why?
|
| Brachytherapy | 1 | 2019 | 977 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 702 | 0.030 |
Why?
|
| DNA Replication | 1 | 2017 | 744 | 0.030 |
Why?
|
| Recurrence | 1 | 2021 | 4758 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1586 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2015 | 665 | 0.030 |
Why?
|
| Diphosphonates | 1 | 2014 | 262 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 6942 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2012 | 207 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 999 | 0.030 |
Why?
|
| Adenine Nucleotides | 1 | 2014 | 351 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2002 | 5710 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 2055 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2012 | 204 | 0.030 |
Why?
|
| Consensus | 1 | 2016 | 978 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 2013 | 219 | 0.030 |
Why?
|
| Everolimus | 1 | 2013 | 415 | 0.020 |
Why?
|
| Cystectomy | 1 | 2015 | 623 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2014 | 731 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 604 | 0.020 |
Why?
|
| Risk Factors | 2 | 2020 | 17523 | 0.020 |
Why?
|
| Bone Density | 1 | 2014 | 476 | 0.020 |
Why?
|
| Arabinonucleosides | 1 | 2014 | 437 | 0.020 |
Why?
|
| Computational Biology | 1 | 2017 | 1271 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2009 | 3536 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2014 | 825 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 544 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2014 | 1021 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2014 | 953 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 754 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2015 | 1987 | 0.020 |
Why?
|
| Drug Design | 1 | 2011 | 375 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 448 | 0.020 |
Why?
|
| Vidarabine | 1 | 2014 | 1341 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2010 | 246 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 4143 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 2307 | 0.020 |
Why?
|
| Niacinamide | 1 | 2010 | 421 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2009 | 388 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 1162 | 0.020 |
Why?
|
| Cell Separation | 1 | 2009 | 612 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 4892 | 0.020 |
Why?
|
| Mitochondria | 1 | 2014 | 1282 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 1479 | 0.020 |
Why?
|
| Histones | 1 | 2014 | 1466 | 0.020 |
Why?
|
| Incidence | 1 | 2016 | 5673 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 2173 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2014 | 2022 | 0.020 |
Why?
|
| Monocytes | 1 | 2009 | 788 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2012 | 3842 | 0.020 |
Why?
|
| Hospitalization | 1 | 2013 | 2083 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 7702 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 6295 | 0.020 |
Why?
|
| Quinazolines | 1 | 2009 | 923 | 0.020 |
Why?
|
| Caspase 10 | 1 | 2003 | 21 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 815 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 43 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 329 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 5687 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 4320 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 4844 | 0.010 |
Why?
|
| Azacitidine | 1 | 2009 | 1149 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2009 | 1299 | 0.010 |
Why?
|
| Palliative Care | 1 | 2014 | 2037 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 5539 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2992 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2003 | 1459 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 2450 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2003 | 929 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2003 | 1390 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 6915 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 31252 | 0.010 |
Why?
|